InvestorsHub Logo
Post# of 252595
Next 10
Followers 60
Posts 11531
Boards Moderated 0
Alias Born 07/16/2006

Re: DewDiligence post# 220527

Friday, 08/17/2018 12:43:05 PM

Friday, August 17, 2018 12:43:05 PM

Post# of 252595
While the 51.7% versus 47.4% is pretty close to equilibrium, any future growth in Mavyret's new patient share might entice Gild to change their pricing strategy to maintain market share.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.